Showing results (231-240 of 247) with videos related to

Sort By:
Pageof 25
European Heart Journal|June 30, 2016
Geographic variations in the PARADIGM-HF heart failure trialSøren Lund Kristensen, Felipe Martinez, Pardeep S Jhund, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 28, 2022
Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled TrialHiddo J L Heerspink, Remo H M Furtado, Otavio Berwanger, et al.
Nature Chemical Biology|April 28, 2025
Monitoring in real time and far-red imaging of H2O2 dynamics with subcellular resolutionJustin Daho Lee, Amanda Nguyen, Chelsea E Gibbs, et al.
Circulation|August 27, 2022
Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER TrialJawad H Butt, Pardeep S Jhund, Jan Belohlávek, et al.
Circulation|November 19, 2019
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HFJohn J V McMurray, Alice M Jackson, Carolyn S P Lam, et al.
Circulation. Heart Failure|April 19, 2021
Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialJasper Tromp, Brian L Claggett, Jiankang Liu, et al.
The New England Journal of Medicine|September 3, 2019
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionScott D Solomon, John J V McMurray, Inder S Anand, et al.
European Journal of Heart Failure|December 17, 2021
Diabetes and pre-diabetes in patients with heart failure and preserved ejection fractionAlice M Jackson, Rasmus Rørth, Jiankang Liu, et al.
The Lancet. Diabetes & Endocrinology|July 24, 2021
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trialMikhail N Kosiborod, Russell Esterline, Remo H M Furtado, et al.
JACC. Heart Failure|March 4, 2022
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER TrialScott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
Pageof 25